Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease (Q45295696)

11 December 2017

title

Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease (English)

1 reference

11 December 2017

0 references

1 reference

2

1 reference

11 December 2017

3

1 reference

11 December 2017

5

1 reference

11 December 2017

6

1 reference

11 December 2017

Marta Anglada-Huguet

1

1 reference

11 December 2017

Alfonsa Zamora-Moratalla

series ordinal

4

1 reference

11 December 2017

publication date

7 November 2013

1 reference

11 December 2017

published in

Molecular Neurobiology

1 reference

11 December 2017

volume

49

1 reference

11 December 2017

issue

2

1 reference

11 December 2017

page(s)

784-795

1 reference

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Evidence for specific cognitive deficits in preclinical Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation--a longitudinal follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Differential loss of striatal projection neurons in Huntington disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Huntington's disease: a synaptopathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Huntington's disease: from molecular pathogenesis to clinical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Prostaglandin EP1 receptor contributes to excitotoxicity and focal ischemic brain damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Contributions of cyclooxygenase-2 to neuroplasticity and neuropathology of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Prostaglandin E2-induced synaptic plasticity in neocortical networks of organotypic slice cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Altered hippocampal long-term synaptic plasticity in mice deficient in the PGE2 EP2 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Prostanoid receptors: subtypes and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

PGE2 EP1 receptor exacerbated neurotoxicity in a mouse model of cerebral ischemia and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Prostaglandin E2 acts on EP1 receptor and amplifies both dopamine D1 and D2 receptor signaling in the striatum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Emerging roles of PGE2 receptors in models of neurological disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Brain-derived neurotrophic factor modulates the severity of cognitive alterations induced by mutant huntingtin: involvement of phospholipaseCgamma activity and glutamate receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Conditional BDNF release under pathological conditions improves Huntington's disease pathology by delaying neuronal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Activation of Elk-1 participates as a neuroprotective compensatory mechanism in models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Reduced calcineurin protein levels and activity in exon-1 mouse models of Huntington's disease: role in excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

BDNF regulation under GFAP promoter provides engineered astrocytes as a new approach for long-term protection in Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Stabilizing effects of extracellular ATP on synaptic efficacy and plasticity in hippocampal pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Disruption of striatal glutamatergic transmission induced by mutant huntingtin involves remodeling of both postsynaptic density and NMDA receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Inhibition of Rho kinases enhances the degradation of mutant huntingtin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Neuronal aggregates are associated with phenotypic onset in the R6/2 Huntington's disease transgenic mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Antagonism of neuronal prostaglandin E(2) receptor subtype 1 mitigates amyloid β neurotoxicity in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Calcium ions in neuronal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Prostaglandin E2 enhances mitogen-activated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Dopaminergic signaling and striatal neurodegeneration in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Impaired synaptic plasticity in mice carrying the Huntington's disease mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Comparative analysis of pathology and behavioural phenotypes in mouse models of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Dantrolene is neuroprotective in Huntington's disease transgenic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Calcium - a life and death signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12035-013-8556-X

Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation.

21 January 2018

1 reference

12 December 2020

Prostaglandin EP4 receptor agonist protects against acute neurotoxicity

1 reference

12 December 2020

Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.

1 reference

12 December 2020

Neuropathological classification of Huntington's disease

1 reference

12 December 2020

PGE(2) receptor EP1 renders dopaminergic neurons selectively vulnerable to low-level oxidative stress and direct PGE(2) neurotoxicity

1 reference

12 December 2020

10.1007/S12035-013-8556-X

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1014408350

0 references

1 reference